Antibody Products for
COVID-19 (SARS-CoV-2) Research

Antibodies for SARS-CoV-2 Research

Antibodies are a critical part of COVID-19 research as they are used to gain insight into the immune system response to SARS-CoV-2 infections. Relevant applications of antibodies include the detection of biomarkers such as cytokines or to detect CD4 and CD8 T cells, as well as inclusion in serological assays for the monitoring of immunoglobulins. Our wide selection of reliable antibodies and related products include reagents that may be relevant for supporting SARS-CoV-2 research. For Research Use Only. Not For Use In Diagnostic Procedures.

Antibodies for Cytokine, CD4, & CD8 Detection

When the immune system senses a pathogen, such as SARS-CoV-2, it releases certain soluble substances in response. Viral infection can lead to an uncontrolled increase in cytokine levels known as a “cytokine storm”. The increase in levels of biomarkers such as IL-10, IL-1β, IP-10, IFNγ, and IL-1RA is considered an indication of viral infection severity and is shown in early studies to be associated with SARS-CoV-2 infection 1,2. Another study found IL-6 levels increased with SARS-CoV-2 infection 3. Other indicators of viral infection include increases in IFNα, IL-2RA, and C-reactive protein (CRP). An additional finding sometimes associated with SARS-CoV-2 infection is the decline in the levels of CD4 and CD8 T cells 4. Antibodies may be useful for studying infection severity by detecting the level of cytokines, CD4 T cells, and CD8 T cells.

Antibodies for Serological Monitoring

Antibody-based serology tests are useful in identifying subjects with an adaptive immune response to the SARS-CoV-2 virus. As with most infections, the antibody response to SARS-CoV-2 infection starts with early production of IgM and/or IgA antibodies, followed by the longer-lasting and more specific IgG response 5,6.

Our portfolio provides a variety of antibodies for human immunoglobulin (Ig) detection for seroprevalence studies. It includes conjugated antibodies linked to a label and used for a diverse range of assay techniques such as detection, purification, sorting, and microscopy applications. Our antibodies are validated in various immunoapplications and a variety of hosts.


Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 395(10229):1033-1034.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395(10223):497-506.
Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46(5):846-848.
Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front. Immunol.. 11
Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, Pitkäpaasi M, Blomqvist S, Rönkkö E, Kantele A, et al. 2020. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. 25(11):
Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, Faggian D, Matricardi P, Plebani M. 2020. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clinica Chimica Acta. 507164-166.

For Research Use Only. Not for use in diagnostic procedures.

Unless otherwise stated in the Product(s) specifications, any Antibody product is sold for internal research use only and may not be used for any other purpose, which includes but is not limited to, any commercial, diagnostic, or therapeutic use. Our validation processes pertain only to research uses and do not confirm or assure that our antibodies can be used for any unauthorized uses as set forth herein.